French Fashion Giant LVMH Posts 23% Revenue Growth In FY22

French luxury fashion house LVMH-Moet Hennessy Louis Vuitton (OTC:LVMHF) registered FY22 sales growth of 23% year-on-year to €79.2 billion. Fashion & Leather Goods organic…
  • French luxury fashion house LVMH-Moet Hennessy Louis Vuitton (OTC:LVMHF) registered FY22 sales growth of 23% year-on-year to €79.2 billion.
  • Fashion & Leather Goods organic revenue rose 20%, with Louis Vuitton, Christian Dior, Celine, Fendi, Loro Piana, Loewe, and Marc Jacobs gaining global market share.
  • Profit from recurring operations stood at €21.1 billion, a 23% increase Y/Y and the operating margin remained flat.
  • Europe, the U.S., and Japan rose sharply, benefiting from strong demand from local customers and the recovery of international travel. 
  • Also Read: Luxury Goods Company LVMH CEO Bernard Arnault’s Daughter Takes Helm Of Christian Dior
  • Developments in the health situation in China caused a damper on Asia sales.
  • The company had an operating free cash flow of €10.1 billion and a net debt of €9.2 billion.
  • “We approach 2023 with confidence but remain vigilant due to current uncertainties,” said chairman and CEO Bernard Arnault.
  • At the General Meeting of April 20, 2023, LVMH will propose a dividend of €12 per share.
  • Price Action: LVMHF shares closed lower by 2.64% at $847 on Thursday.
  • Photo Via Company
Total
0
Shares
Related Posts
Read More

Another Cannabis Pioneer Expands In Germany Via Acquisition As Experts Say ‘There’s No Stepping Back’ From Legalization Wave

Flora Growth Corp. has entered into a definitive agreement to acquire all of the issued and outstanding shares of Hamburg, Germany-based TruHC Pharma GmbH. The company's latest move to further cement its global footprint comes on the heels of a new German cannabis law that went into effect on April 1, which partially legalized cannabis. The new law allows adults over 18 in Germany to legally possess up to 25 grams of dried cannabis and cultivate up to three marijuana plants at home.As previously announced, Flora agreed to purchase TruHC Pharma GmbH in an all-stock deal in exchange for 2,770,562 of its common shares, valued at $6.4 million.

ACB